{"product_id":"smart-contact-lens-development-profitability","title":"How to Increase Smart Contact Lenses Profitability Through Scale and Pricing","description":"\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"line_top\"\u003e\u003c\/div\u003e\n\u003ch2\u003eSmart Contact Lenses Strategies to Increase Profitability\u003c\/h2\u003e\n\u003cp\u003eSmart Contact Lenses operations can realistically achieve EBITDA margins exceeding 30% by 2028, driven by volume scaling and optimized product mix The high fixed overhead, including $102 million annually for facilities and regulatory compliance, requires rapid unit sales growth to cover costs The InfoLens Basic product has a 90% gross margin at $700, showing strong operating leverage By 2030, EBITDA is projected to reach over $242 million, but the priority is managing the minimum cash requirement of $7191 million in early 2027\n\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\" id=\"main_article_image\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #6067F2;\"\u003e7 Strategies to Increase Profitability of \u003c\/span\u003eSmart Contact Lenses\u003c\/h2\u003e\u003cbr\u003e\n\u003ctable id=\"dwnld_tbl_id\"\u003e\n\u003ctr\u003e\n\u003cth\u003e#\u003c\/th\u003e\n\u003cth\u003eStrategy\u003c\/th\u003e\n\u003cth\u003eProfit Lever\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eExpected Impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eVolume Pricing Optimization\u003c\/td\u003e\n\u003ctd\u003ePricing\u003c\/td\u003e\n\u003ctd\u003eUse tiered pricing for distributors and clinical partners to drive volume needed to absorb the $2075 million annual fixed overhead.\u003c\/td\u003e\n\u003ctd\u003eDrive volume needed to absorb the $2075 million annual fixed overhead.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eOptimize Product Mix\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003ePrioritize HealthLens Advanced ($6,000 ASP, 887% GM) over InfoLens Basic ($700 ASP, 90% GM).\u003c\/td\u003e\n\u003ctd\u003eBoost absolute dollar contribution per unit by $4,690 (HealthLens vs InfoLens).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eScale COGS Reduction\u003c\/td\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003eNegotiate lower raw material ($25) and micro-component ($30) costs based on 200,000+ unit commitment by 2030.\u003c\/td\u003e\n\u003ctd\u003eDrop unit COGS by 10–15% through material negotiation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003eControl Fixed Overhead\u003c\/td\u003e\n\u003ctd\u003eOPEX\u003c\/td\u003e\n\u003ctd\u003eAudit the $15,000 monthly regulatory spend and $10,000 R\u0026amp;D consumables budget against clinical trial milestones.\u003c\/td\u003e\n\u003ctd\u003eEnsure fixed spend is tightly aligned with key clinical trial milestones, defintely controlling burn.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003eIncrease Labor Efficiency\u003c\/td\u003e\n\u003ctd\u003eProductivity\u003c\/td\u003e\n\u003ctd\u003eInvest in automation beyond the initial $25 million CAPEX to reduce Direct Assembly Labor costs ($8 per unit).\u003c\/td\u003e\n\u003ctd\u003eManage the cost of scaling manufacturing FTEs (1 to 20 by 2030).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003eReduce Variable Opex\u003c\/td\u003e\n\u003ctd\u003eOPEX\u003c\/td\u003e\n\u003ctd\u003eDevelop internal distribution channels to cut reliance on third-party logistics providers.\u003c\/td\u003e\n\u003ctd\u003eCut the 30% distribution cost percentage of revenue by at least one point.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003eReview IP Licensing Fees\u003c\/td\u003e\n\u003ctd\u003eOPEX\u003c\/td\u003e\n\u003ctd\u003eChallenge or renegotiate the 10% IP Licensing Fees structure based on revenue.\u003c\/td\u003e\n\u003ctd\u003eLower the high percentage cost as revenue scales toward $240 million by 2030.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"dwnld_btn_div\"\u003e\u003cbutton id=\"dwnld_btn_id\" class=\"dwnld_btn_clss\"\u003eDownload Table in XLSX\u003c\/button\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e \u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eWhat is the true fully-loaded unit cost across all product lines?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eThe gross margin for the Smart Contact Lenses product mix is high, sitting between \u003cstrong\u003e88.7%\u003c\/strong\u003e for the premium line and \u003cstrong\u003e90%\u003c\/strong\u003e for the basic offering, meaning the fully-loaded unit cost is low relative to the selling price. To understand the total cost structure, you need to map these COGS figures against overhead, which you can start estimating by reviewing \u003ca href=\"\/blogs\/startup-costs\/smart-contact-lens-development\"\u003eWhat Is The Estimated Cost To Launch Your Smart Contact Lenses Business?\u003c\/a\u003e\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eBasic Line Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eInfoLens Basic yields a \u003cstrong\u003e90%\u003c\/strong\u003e gross margin.\u003c\/li\u003e\n\u003cli\u003eThe unit cost (COGS) is only \u003cstrong\u003e$70\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThis leaves $630 per unit for overhead coverage.\u003c\/li\u003e\n\u003cli\u003eThis margin is strong for a hardware product.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eAdvanced Line Cost Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eHealthLens Advanced has a \u003cstrong\u003e$6,000\u003c\/strong\u003e Average Selling Price (ASP).\u003c\/li\u003e\n\u003cli\u003eIts cost of goods sold is \u003cstrong\u003e$680\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe resulting gross margin is \u003cstrong\u003e88.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe difference in margin is defintely small given the price gap.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eWhich specific expense category offers the greatest leverage for reduction?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eReducing the \u003cstrong\u003e8% variable operating expenses\u003c\/strong\u003e offers the fastest path to improving monthly cash flow for the Smart Contact Lenses business because it immediately boosts the contribution margin on every unit sold, unlike the large, discrete $25 million specialized manufacturing equipment CAPEX; founders should defintely review Have You Considered How To Outline The Market Strategy For Smart Contact Lenses? for context on revenue drivers impacting these costs.\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eVariable Cost Leverage is Immediate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eVariable costs, like commissions and distribution, are paid when revenue hits.\u003c\/li\u003e\n\u003cli\u003eIf you sell 10,000 units generating $1 million in sales, 8% is $80,000 in fees.\u003c\/li\u003e\n\u003cli\u003eCutting that 8% to 6% saves \u003cstrong\u003e$16,000\u003c\/strong\u003e in cash flow that month.\u003c\/li\u003e\n\u003cli\u003eThis margin improvement flows straight to the bottom line today.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eCAPEX is a Financing Decision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eThe \u003cstrong\u003e$25 million\u003c\/strong\u003e specialized manufacturing equipment is a long-term asset purchase.\u003c\/li\u003e\n\u003cli\u003eReducing this cost improves financing terms or reduces initial cash burn.\u003c\/li\u003e\n\u003cli\u003eIt doesn't change the unit economics or monthly operating contribution margin.\u003c\/li\u003e\n\u003cli\u003eCash flow improvement from CAPEX is slower, tied to depreciation schedules or debt repayment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eHow quickly can manufacturing capacity scale to meet the 200,000+ unit demand forecast?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eScaling manufacturing for the \u003cstrong\u003e200,000+ unit\u003c\/strong\u003e forecast hinges on resolving the R\u0026amp;D staffing timeline before regulatory hurdles become the primary constraint, especially considering the ongoing cost of compliance. Before diving deep into operational metrics like Customer Lifetime Value (CLV) or Customer Acquisition Cost (CAC), founders must track the time-to-market dictated by specialized hiring, which is critical when assessing \u003ca href=\"\/blogs\/kpi-metrics\/smart-contact-lens-development\"\u003eWhat Is The Most Important Metric To Measure The Success Of Smart Contact Lenses Business?\u003c\/a\u003e\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eRegulatory Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eRegulatory affairs requires a \u003cstrong\u003e$15,000\u003c\/strong\u003e monthly fixed spend.\u003c\/li\u003e\n\u003cli\u003eThis cost is predictable overhead, not a volume blocker.\u003c\/li\u003e\n\u003cli\u003eYou must fund this spend regardless of production rate.\u003c\/li\u003e\n\u003cli\u003eIt’s a baseline cost to maintain market access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eR\u0026amp;D Staffing Bottleneck\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eR\u0026amp;D staffing must grow from \u003cstrong\u003e1 FTE to 10 FTE\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe target date for this staffing level is \u003cstrong\u003e2030\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHiring pace dictates product finalization timelines.\u003c\/li\u003e\n\u003cli\u003eSlow hiring definitely delays capacity readiness for volume.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eAre we willing to delay the launch of high-margin products like AuraLens Elite to focus resources on scaling InfoLens Basic volume?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eDelaying the launch of the high-margin AuraLens Elite to prioritize scaling InfoLens Basic volume is a viable strategy only if the immediate volume provides enough leverage to negotiate down your \u003cstrong\u003e10% IP Licensing Fee\u003c\/strong\u003e, but founders must first understand the regulatory hurdles; \u003ca href=\"\/blogs\/how-to-open\/smart-contact-lens-development\"\u003eHave You Considered The Necessary Steps To Legally Register And Launch Smart Contact Lenses Business?\u003c\/a\u003e\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eTrading Margin for Fee Reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eScaling Basic volume buys negotiation power against IP holders.\u003c\/li\u003e\n\u003cli\u003eIf Basic volume hits \u003cstrong\u003e$5M\u003c\/strong\u003e in year one, aim to cut the \u003cstrong\u003e10%\u003c\/strong\u003e fee to \u003cstrong\u003e7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThat \u003cstrong\u003e3%\u003c\/strong\u003e swing on $5M is \u003cstrong\u003e$150,000\u003c\/strong\u003e saved annually, offsetting delayed Elite revenue.\u003c\/li\u003e\n\u003cli\u003eHigh-margin Elite products often carry higher initial IP costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eCompetitive Advantage Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eElite likely contains the core IP differentiator for the premium market.\u003c\/li\u003e\n\u003cli\u003eDelaying Elite risks letting competitors define the high-end augmented reality space first.\u003c\/li\u003e\n\u003cli\u003eIf Elite has a \u003cstrong\u003e70%\u003c\/strong\u003e gross margin versus Basic’s \u003cstrong\u003e45%\u003c\/strong\u003e, the opportunity cost is steep.\u003c\/li\u003e\n\u003cli\u003eFocusing only on Basic volume builds a low-end moat, not a high-end barrier.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e \u003cdiv class=\"card_smpl\"\u003e\n\n\u003cdiv class=\"double_border\"\u003e\n\n\u003cdiv class=\"card_smpl_header\"\u003e\n\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-plus-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\n\n\u003ch3\u003eKey Takeaways\u003c\/h3\u003e\n\n\u003c\/div\u003e\n\n\u003cul class=\"lst_crct_blog\"\u003e\n\n\u003cli\u003eRapid volume scaling is the immediate imperative to overcome high initial fixed overhead and manage the projected $7.191 million minimum cash requirement by early 2027.\u003c\/li\u003e\n\n\u003cli\u003eThe business benefits from massive operating leverage due to gross margins near 90% on entry-level products, making sustained high volume the key to achieving the 30% EBITDA margin target by 2028.\u003c\/li\u003e\n\n\u003cli\u003eProfitability optimization requires prioritizing the product mix toward higher absolute dollar contribution items, such as HealthLens Advanced ($5,320 contribution), over sheer unit volume alone.\u003c\/li\u003e\n\n\u003cli\u003eLong-term margin defense depends on aggressively negotiating raw material costs and challenging fixed expenses like the 10% IP licensing fee as revenue scales toward $240 million.\u003c\/li\u003e\n\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStrategy 1\n: \u003cspan style=\"color: #126CFF;\"\u003eVolume Pricing Optimization\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eVolume Pricing Mandate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eYou must defintely structure tiered pricing for large buyers to generate the necessary sales velocity right now. This addresses the massive \u003cstrong\u003e$2,075 million annual fixed overhead\u003c\/strong\u003e hanging over the business. Volume discounts incentivize the upfront commitment needed to cover these structural costs.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl_2\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-tips-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eFixed Overhead Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eThe \u003cstrong\u003e$2,075 million annual fixed overhead\u003c\/strong\u003e represents the cost of maintaining core operations, including specialized cleanroom facilities, regulatory filing expenses, and long-term R\u0026amp;D amortization. Estimating this requires summing monthly regulatory compliance (\u003cstrong\u003e$15,000\u003c\/strong\u003e) and R\u0026amp;D consumables (\u003cstrong\u003e$10,000\u003c\/strong\u003e) across 12 months, plus larger capital infrastructure depreciation.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eFixed costs require immediate volume coverage.\u003c\/li\u003e\n\u003cli\u003eCompliance spend must align with milestones.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D consumables are a non-negotiable base cost.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eDriving Volume Commitments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eTiered pricing immediately pulls volume forward. Offer steep discounts only when distributors commit to minimum annual purchase volumes, perhaps \u003cstrong\u003e100,000 units\u003c\/strong\u003e for Tier 1 status. This structure protects the high \u003cstrong\u003e$6,000 ASP\u003c\/strong\u003e of the HealthLens Advanced product while ensuring base coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eLink discounts directly to purchase thresholds.\u003c\/li\u003e\n\u003cli\u003ePrioritize high-margin HealthLens Advanced sales.\u003c\/li\u003e\n\u003cli\u003eUse clinical partners for guaranteed base orders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\u003cdiv class=\"double_border\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-pin-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eLeveraging Volume for COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eVolume commitments are critical leverage points for future cost reduction negotiations. If distributors commit to \u003cstrong\u003e200,000+ units by 2030\u003c\/strong\u003e, you gain bargaining power to demand lower raw material costs, potentially dropping InfoLens Basic COGS by \u003cstrong\u003e10–15%\u003c\/strong\u003e. Don't offer discounts without securing volume guarantees first.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStrategy 2\n: \u003cspan style=\"color: #126CFF;\"\u003eOptimize Product Mix\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003ePrioritize Dollar Profit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003ePrioritize selling the high-end lens; the absolute dollar profit drives profitability faster than chasing high percentage margins on low-priced items. HealthLens Advanced yields \u003cstrong\u003e$5,320\u003c\/strong\u003e in contribution per unit, dwarfing InfoLens Basic’s \u003cstrong\u003e$630\u003c\/strong\u003e, even though the Basic model has a lower \u003cstrong\u003e90%\u003c\/strong\u003e Gross Margin. You need fewer sales to move the needle.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-tips-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eContribution Break-Even Volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eTo cover fixed overhead, you need far fewer high-margin sales. If fixed costs are \u003cstrong\u003e$2,075 million\u003c\/strong\u003e annually, selling only \u003cstrong\u003e392,358\u003c\/strong\u003e HealthLens Advanced units gets you there ($2,075M \/ $5,320). Selling only InfoLens Basic requires \u003cstrong\u003e3,293,650\u003c\/strong\u003e units ($2,075M \/ $630). That’s a massive difference in required sales velocity.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eAdvanced ASP: \u003cstrong\u003e$6,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eBasic ASP: \u003cstrong\u003e$700\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAdvanced GM: \u003cstrong\u003e887%\u003c\/strong\u003e (as stated)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl_2\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eSteering Sales Efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eDirect your sales team and marketing spend toward the \u003cstrong\u003e$6,000\u003c\/strong\u003e Advanced unit. Tech-savvy professionals are your best target for this product line. It's defintely important to avoid discounting the Advanced lens just to match the volume of the Basic product, as that destroys needed dollar contribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eTarget high-value segments first.\u003c\/li\u003e\n\u003cli\u003eTie sales compensation to dollar contribution.\u003c\/li\u003e\n\u003cli\u003eFocus marketing on performance enhancement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\u003cdiv class=\"double_border\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-pin-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eKey Profit Driver\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003ePercentage Gross Margin (GM) is a vanity metric when unit economics vary this much. Always calculate and track \u003cstrong\u003eContribution Per Unit\u003c\/strong\u003e first; it’s the truest measure of how much each sale helps cover your \u003cstrong\u003e$2,075 million\u003c\/strong\u003e annual fixed overhead.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStrategy 3\n: \u003cspan style=\"color: #126CFF;\"\u003eScale COGS Reduction\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eForce COGS Reduction Now\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eSecure future volume discounts immediately to cut unit costs. Commit to \u003cstrong\u003e200,000+ units by 2030\u003c\/strong\u003e to force suppliers down on the \u003cstrong\u003e$25\u003c\/strong\u003e raw material and \u003cstrong\u003e$30\u003c\/strong\u003e micro-component costs, targeting a \u003cstrong\u003e10–15%\u003c\/strong\u003e reduction in overall COGS for the InfoLens Basic line. That's how you build margin early.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl_2\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-tips-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eMaterial Cost Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eThese material costs define the baseline Cost of Goods Sold (COGS) for the entry-level InfoLens Basic. The \u003cstrong\u003e$25\u003c\/strong\u003e raw material and \u003cstrong\u003e$30\u003c\/strong\u003e micro-component costs are direct inputs. If your current unit COGS is, say, $100, a 15% reduction saves $15 per unit, which is critical when scaling toward the \u003cstrong\u003e2030\u003c\/strong\u003e volume targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eRaw material cost: $25\/unit.\u003c\/li\u003e\n\u003cli\u003eMicro-component cost: $30\/unit.\u003c\/li\u003e\n\u003cli\u003eGoal: 10–15% COGS drop.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eLocking In Savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eYou must use future volume as collateral today; suppliers won't move unless the commitment is binding. Don't just ask for a discount; present a firm, multi-year roadmap tied to specific manufacturing milestones. If onboarding takes 14+ days, churn risk rises.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eTie discounts to volume tiers.\u003c\/li\u003e\n\u003cli\u003eUse 2030 projections as leverage.\u003c\/li\u003e\n\u003cli\u003eAvoid incremental price creep later.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\u003cdiv class=\"double_border\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-pin-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eVolume Leverage Point\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eNegotiating these component prices now locks in margin before you hit scale. If you secure the \u003cstrong\u003e15%\u003c\/strong\u003e reduction, that margin flows straight through to the bottom line, unlike revenue adjustments. This defintely secures profitability well before the \u003cstrong\u003e2030\u003c\/strong\u003e volume milestone is reached.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStrategy 4\n: \u003cspan style=\"color: #126CFF;\"\u003eControl Fixed Overhead\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eAudit Fixed Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eYou must tie your \u003cstrong\u003e$25,000\u003c\/strong\u003e monthly fixed spend directly to clinical milestones now. Unlinked regulatory and R\u0026amp;D costs burn cash unnecessarily before revenue starts. This spending needs clear go\/no-go triggers tied to trial phases for better cash management.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-tips-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eCost Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eRegulatory compliance costs \u003cstrong\u003e$15,000\u003c\/strong\u003e monthly, covering essential filings and quality system upkeep. R\u0026amp;D consumables run \u003cstrong\u003e$10,000\u003c\/strong\u003e monthly for necessary trial materials. These are fixed until the next phase gate opens. Estimate requires tracking specific submission deadlines and consumable burn rates per cohort.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eCompliance covers \u003cstrong\u003e$15k\u003c\/strong\u003e\/month for upkeep.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D uses \u003cstrong\u003e$10k\u003c\/strong\u003e for trial supplies.\u003c\/li\u003e\n\u003cli\u003eCosts must map to trial phase gates.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl_2\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eCut Waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eDo not pay fixed compliance fees during trial pauses or delays. Negotiate milestone-based billing with external regulatory consultants immediately. For R\u0026amp;D, lock in lower pricing for consumables based on projected Phase 2 volumes, not just current needs. This defintely saves cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eNegotiate consulting retainers down 20%.\u003c\/li\u003e\n\u003cli\u003eLink R\u0026amp;D spending to trial progress.\u003c\/li\u003e\n\u003cli\u003eAvoid paying for idle readiness.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\u003cdiv class=\"double_border\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-pin-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eRunway Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eIf clinical trials slip past the planned Q4 2025 target, immediately trigger a review of all external compliance retainers. Every month spent paying for readiness without active trial progression is \u003cstrong\u003e$25,000\u003c\/strong\u003e lost runway. That money should fund direct assembly labor instead.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStrategy 5\n: \u003cspan style=\"color: #126CFF;\"\u003eIncrease Labor Efficiency\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eAutomate Labor Now\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eScaling manufacturing means labor costs balloon unless you automate aggressively now. Reducing the \u003cstrong\u003e$8 per unit\u003c\/strong\u003e assembly cost for InfoLens Basic is critical as you plan to hire \u003cstrong\u003e19 more FTEs\u003c\/strong\u003e by 2030. Future automation investments must target this direct labor line item specifically.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl_2\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-tips-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eDefining Assembly Labor Cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eDirect Assembly Labor covers the hands-on work building the lenses. For InfoLens Basic, this cost is set at \u003cstrong\u003e$8 per unit\u003c\/strong\u003e, excluding the initial \u003cstrong\u003e$25 million CAPEX\u003c\/strong\u003e for baseline machinery. Estimate future costs by multiplying planned unit volume by the target reduced labor rate per unit.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eInput: InfoLens Basic units produced.\u003c\/li\u003e\n\u003cli\u003eMetric: \u003cstrong\u003e$8\u003c\/strong\u003e direct labor per unit.\u003c\/li\u003e\n\u003cli\u003eScale: Manage growth from \u003cstrong\u003e1 to 20 FTEs\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eControlling FTE Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eYou must automate beyond the initial setup to control headcount growth. Every new FTE added after the first one represents increased overhead risk if output per person doesn't rise. Target a \u003cstrong\u003e50% reduction\u003c\/strong\u003e in the $8 labor cost through advanced robotics or process redesign.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eAvoid hiring for routine tasks.\u003c\/li\u003e\n\u003cli\u003eAutomate assembly processes first.\u003c\/li\u003e\n\u003cli\u003eEnsure new CAPEX targets labor reduction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\u003cdiv class=\"double_border\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-pin-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eAutomation ROI Check\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eIf you plan to hit high volumes by 2030, the investment thesis must prove that automation saves more than it costs in the long run. Don't let manufacturing headcount grow linearly; that path guarantees margin erosion. Defintely budget for Phase Two automation now.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStrategy 6\n: \u003cspan style=\"color: #126CFF;\"\u003eReduce Variable Opex\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eCut Distribution Drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eThird-party logistics costs are currently eating \u003cstrong\u003e30%\u003c\/strong\u003e of your revenue stream. Building internal distribution channels is how you start reclaiming that margin, targeting a reduction of at least \u003cstrong\u003eone full percentage point\u003c\/strong\u003e immediately.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-tips-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eModel Distribution Spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eDistribution costs cover the variable expense of getting the smart lenses to the customer or clinical site via external carriers. You need your projected annual revenue and the current \u003cstrong\u003e30%\u003c\/strong\u003e allocation to calculate the dollar impact. If revenue hits \u003cstrong\u003e$100 million\u003c\/strong\u003e, that’s \u003cstrong\u003e$30 million\u003c\/strong\u003e leaving the business just for shipping and handling.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eCalculate current annual logistics spend\u003c\/li\u003e\n\u003cli\u003eProject savings for every 1% reduction\u003c\/li\u003e\n\u003cli\u003eIdentify high-volume geographic clusters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl_2\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eInternalize Fulfillment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eTo chip away at that \u003cstrong\u003e30%\u003c\/strong\u003e, you must control the last mile, especially as you scale toward \u003cstrong\u003e$240 million\u003c\/strong\u003e by 2030. If you cut distribution costs to \u003cstrong\u003e29%\u003c\/strong\u003e, you keep \u003cstrong\u003e$1 million\u003c\/strong\u003e extra for every $100 million in sales. Defintely start small, perhaps using internal staff for direct-to-clinic deliveries in your core metro area.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eTest internal drivers in dense zones\u003c\/li\u003e\n\u003cli\u003eNegotiate bulk rates for remaining carriers\u003c\/li\u003e\n\u003cli\u003eAvoid service level drops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\u003cdiv class=\"double_border\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-pin-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eWeigh Build vs. Buy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eBuilding an internal channel requires capital outlay, which competes with your planned \u003cstrong\u003e$25 million CAPEX\u003c\/strong\u003e for manufacturing automation. You must model the payback period for that investment against the guaranteed, perpetual margin improvement gained by shedding third-party fees.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eStrategy 7\n: \u003cspan style=\"color: #126CFF;\"\u003eReview IP Licensing Fees\n\u003c\/span\u003e\n\u003c\/h2\u003e\u003cbr\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eRecalculate IP Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eThe \u003cstrong\u003e10% IP Licensing Fee\u003c\/strong\u003e structure is a major long-term margin killer, costing you \u003cstrong\u003e$24 million\u003c\/strong\u003e annually if you hit the \u003cstrong\u003e$240 million\u003c\/strong\u003e revenue target by 2030. You must renegotiate this percentage now before scaling locks it in. This cost eats profit directly, defintely. \u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl_2\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-tips-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eUnderstanding the Cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eThis fee covers the right to use the core intellectual property (IP) for the smart lens technology. Estimate this cost by multiplying projected annual revenue by the \u003cstrong\u003e10%\u003c\/strong\u003e rate. It sits directly below Gross Profit on the income statement, acting as a high-percentage operating expense that scales perfectly with sales volume. \u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eInputs: Revenue projections, 10% rate.\u003c\/li\u003e\n\u003cli\u003eImpact: Scales with every dollar sold.\u003c\/li\u003e\n\u003cli\u003eAction: Model fixed fee alternatives today.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eNegotiation Tactics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eA fixed fee structure is usually better once volume is proven, protecting margins when revenue spikes unexpectedly. Since you project high growth, push for a tiered structure that steps down from 10% as revenue crosses certain thresholds, say \u003cstrong\u003e$50 million\u003c\/strong\u003e. Don't just accept the starting terms. \u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003ePropose a step-down percentage.\u003c\/li\u003e\n\u003cli\u003eBenchmark against similar tech licensing deals.\u003c\/li\u003e\n\u003cli\u003eTie payment to R\u0026amp;D milestones instead of gross sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\u003cdiv class=\"double_border\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-20-blog-pin-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eMargin Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp\u003eIf you fail to address this \u003cstrong\u003e10%\u003c\/strong\u003e rate, you are essentially capping your maximum achievable gross margin at \u003cstrong\u003e90%\u003c\/strong\u003e, regardless of how efficient manufacturing gets. This structure punishes operational success, defintely something founders must fight for.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e","brand":"FinancialModelsLab","offers":[{"title":"Default Title","offer_id":49304426381555,"sku":"smart-contact-lens-development-profitability","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0522\/6191\/2762\/files\/smart-contact-lens-development-profitability.webp?v=1782692298","url":"https:\/\/financialmodelslab.com\/products\/smart-contact-lens-development-profitability","provider":"Financial Models Lab","version":"1.0","type":"link"}